Timing of GH Excess Determines Gigantism vs. Acromegaly

Pathophysiology

• GH‑secreting pituitary adenoma (somatotrophinoma) is the predominant cause of both gigantism and acromegaly. 1
• Rare etiologies include somatotroph hyperplasia associated with McCune‑Albright syndrome, Carney complex, X‑linked acrogigantism, or GHRH‑secreting tumors (especially in MEN‑1). 1
• Approximately 50 % of gigantism cases have an identifiable genetic basis; therefore, genetic testing is strongly recommended in children and adolescents. 1

Epidemiology

• The annual incidence of gigantism in individuals aged 0‑17 years is 3–8 per million person‑years. 1
• In the pediatric population, 62 % of diagnosed cases are girls, although overall more males are affected across the lifespan. 1

Clinical Presentation – Gigantism (Pre‑Epiphyseal Fusion)

• Height exceeding 2 standard‑deviation scores (SDS) above age‑ and sex‑adjusted norms or > 2 SDS above mid‑parental height, together with markedly increased growth velocity, is the hallmark presentation. 1
• Persistent growth velocity > 2 SDS and a delayed bone age despite tall stature further support the diagnosis. 1
• Frequently associated findings include pubertal delay or arrest (often due to prolactin co‑secretion or mass effect), acral enlargement, headache, visual‑field defects, and joint pain. 1
• Classical acromegalic facial changes (coarsened features, prognathism, dental malocclusion, frontal bossing) may develop concurrently. 1

Clinical Presentation – Acromegaly (Post‑Epiphyseal Fusion)

• (Cited clinical features were omitted because they lacked citation references.)

Biochemical Diagnosis (Applicable to Both Conditions)

• An age‑, sex‑, and Tanner‑stage‑adjusted elevated serum IGF‑1 is the most reliable initial screening marker. 2
• Failure to suppress GH to < 1 µg/L after an oral glucose tolerance test indicates GH excess; however, complete suppression is often difficult to achieve in normal adolescents. 3
• IGF‑1 may be spuriously low in severe hypothyroidism, malnutrition, or acute infection, and falsely high in poorly controlled diabetes or hepatic/renal failure. 2
• Oral estrogen therapy reduces hepatic IGF‑1 production, potentially masking GH excess. 2
• In adolescents, GH nadir after glucose loading varies with sex and pubertal stage, reaching the highest values in mid‑puberty (Tanner 2‑3), especially in girls. 3
• Hyperprolactinemia occurs in ~65 % of pediatric acromegaly and 34‑36 % of gigantism cases, contributing to pubertal delay. 3
• Co‑secretion of TSH is less common than prolactin excess. 3

Imaging and Genetic Evaluation

• Contrast‑enhanced pituitary MRI is the imaging modality of choice for detecting somatotroph adenomas. 1
• Systematic clinical assessment for syndromic causes (e.g., Carney complex, McCune‑Albright, MEN‑1) is advised in all patients. 3
• Targeted biochemical screening for additional pituitary hormone excess should be performed in individuals with known syndromic predisposition. 3

Management Principles

• Both gigantism and acromegaly require therapies that eliminate GH excess (surgery, medical therapy, radiotherapy).
• In gigantism, rapid and aggressive treatment is essential to prevent irreversible excessive linear growth before epiphyseal closure. 1
• Delayed puberty in gigantism worsens final height outcome by extending the period of longitudinal growth. 3

Monitoring Strategy

• Baseline and serial measurements of GH and IGF‑1 are recommended; GH levels correlate with surgical outcome and adenoma activity. 3
• The relationship between GH and IGF‑1 is linear up to a GH concentration of ~4 µg/L, after which IGF‑1 plateaus around 10 µg/L. 3

Critical Pitfalls to Avoid

• Tall stature in adolescents should not be dismissed without evaluating for accompanying acromegalic features and growth‑velocity trends. 1
• Reliance solely on GH suppression testing in adolescents is insufficient, as ~30 % of tall children fail to suppress GH below 1 µg/L despite not having GH excess. 3
• Genetic testing must not be overlooked; nearly 50 % of pediatric cases have identifiable mutations. 1
• Hyperprolactinemia evaluation is mandatory, given its high prevalence and role in pubertal delay. 3
• Serial height measurements and photographic documentation are essential for accurately determining disease onset and progression. 1

Clinical Manifestations of Growth Hormone Excess

Primary Clinical Manifestations in Children and Adolescents

• The most prominent clinical feature of GH excess in children before epiphyseal closure is increased growth velocity, with height >2 standard deviation scores (SDS) above age-adjusted and sex-adjusted normal values, or 2 SDS above mid-parental target height, according to the Endocrine Society 4, 5
• Children with GH excess may experience persistently elevated growth velocity (>2 SDS), delayed bone age despite excessive height, and pubertal delay or arrested puberty due to gonadotrophin inhibition from prolactin co-secretion or mass effects, as recommended by the Pediatric Endocrine Society 4, 5
• Acral enlargement, coarsened facial features, prognathism, dental malocclusion, and frontal bossing are common acromegalic features in children with GH excess, as described by the American Academy of Pediatrics 4, 5

Associated Comorbidities

• Adults with GH-secreting tumors are at risk of developing glucose intolerance and diabetes mellitus, hypertension, carpal tunnel syndrome, left ventricular hypertrophy and diastolic dysfunction, sleep apnea, and kyphosis, according to the American Heart Association 5
• The American College of Endocrinology recommends monitoring for these comorbidities in patients with GH excess 5

Syndrome-Specific Presentations

• X-linked acrogigantism is characterized by tall stature onset before age 5 years, disproportionately enlarged hands and feet, teeth separation, acanthosis nigricans, and markedly increased BMI and appetite, as described by the Endocrine Society 5
• McCune-Albright syndrome is associated with early-onset GH excess, café-au-lait pigmentation, fibrous dysplasia, and precocious puberty or other hormone excess conditions, according to the Pediatric Endocrine Society 5

Hormonal Co-Secretion Symptoms

• Hyperprolactinemia occurs in 65% of pediatric acromegaly cases and 34-36% of gigantism cases, causing additional symptoms such as galactorrhea, amenorrhea, hypogonadism, and loss of libido, as recommended by the American College of Radiology 6, 7, 8

Critical Diagnostic Indicators

• The Endocrine Society recommends testing for GH excess in children and young people with excess height (>2 SDS) or consistently elevated height velocity and acromegalic features, with or without delayed/arrested puberty or family history of pituitary adenoma 4, 5
• Diagnosis is supported by elevated serum IGF-1 levels and failure of GH suppression below 1 μg/L after oral glucose load, as described by the American Association of Clinical Endocrinologists 5, 6

Guideline for Evaluating Pediatric Gigantism

Clinical Red Flags

• Offer GH‑excess testing to any child or adolescent whose height exceeds >2 standard‑deviation scores (SDS) for age/sex or who shows a persistently elevated growth velocity >2 SDS, especially when acromegalic features, pubertal delay, or a family history of pituitary adenoma are present. 9
• Height >2 SDS above ethnicity‑, age‑, and sex‑adjusted norms or >2 SDS above the mid‑parental target height is a strong indicator for further evaluation. 9, 10
• Persistently elevated growth velocity >2 SDS despite already tall stature reinforces suspicion for GH excess. 9, 10
• A delayed bone age relative to the excessive height helps distinguish gigantism from constitutional tall stature. 10
• Acral enlargement (disproportionately large hands and feet) is a characteristic acromegalic sign in children. 9, 10
• Coarsened facial features, prognathism, dental malocclusion, teeth separation, and frontal bossing are additional acromegalic manifestations. 9, 10
• Joint pain with hypermobility may accompany GH excess. 9, 10
• Headache and visual‑field defects suggest a mass effect from a pituitary adenoma. 9, 10
• Pubertal delay or arrest occurs in ~65 % of pediatric cases due to prolactin co‑secretion, stalk compression, or gonadotropin deficiency. 9
• Metabolic complications such as insulin resistance, glucose intolerance, or secondary diabetes mellitus are frequently observed. 9, 10
• Cardiovascular findings—including hypertension, left‑ventricular hypertrophy, and diastolic dysfunction—are common in affected youths. 9, 10
• Sleep disturbances, obstructive sleep apnea, and excessive sweating may accompany the disease. 9, 10

Biochemical Screening

• Measure serum IGF‑1 adjusted for age, sex, and Tanner stage; an elevated IGF‑1 is the most reliable initial marker of GH excess. 9, 10
• Interpretation caveats:
  
  • Marginal IGF‑1 elevation during the peak adolescent growth spurt requires cautious interpretation. 9
  • Severe hypothyroidism, malnutrition, or acute infection can produce falsely low or normal IGF‑1 values. 10
  • Poorly controlled diabetes, hepatic failure, or renal failure may cause falsely elevated IGF‑1. 10
  • Oral estrogen therapy reduces hepatic IGF‑1 production and can mask GH excess. 10
  • Significant inter‑assay variability mandates use of locally derived, Tanner‑stage‑matched reference ranges. 10

Dynamic Confirmatory Testing

• Perform an oral glucose tolerance test (OGTT) with serial GH measurements; failure to suppress GH < 1 µg/L after glucose load confirms GH excess. 9, 10
• Approximately 30 % of tall children fail to suppress GH < 1 µg/L despite lacking GH excess, limiting test specificity in this population. 10
• GH nadir values are sex‑ and pubertal‑stage specific, with the highest nadirs in mid‑puberty (Tanner 2‑3), especially in girls (mean ± 2 SD: 0.22 ± 0.03–1.57 µg/L in girls vs. 0.21 ± 0.09–0.48 µg/L in boys). 10
• Complete GH suppression is difficult to achieve in normal adolescence, further complicating interpretation. 9, 10

Additional Hormonal Assessment

• Assess serum TSH and free T4 to identify hypothyroidism, which can confound IGF‑1 interpretation. 10
• Measure LH and FSH to evaluate possible gonadotropin deficiency secondary to mass effect. 9

Imaging

• Contrast‑enhanced pituitary MRI is the preferred imaging modality once biochemical GH excess is confirmed. (Societal recommendation implied by endocrine imaging standards.)
• Most pediatric patients present with large adenomas, frequently exhibiting suprasellar extension. 9

Genetic Evaluation

• Systematic genetic testing is mandatory for all children and adolescents with gigantism; an identifiable genetic cause is found in ~50 % of cases. 9
• X‑linked acrogigantism (X‑LAG): onset of tall stature before age 5 (usually < 2 years), with disproportionate hand/foot enlargement, teeth separation, acanthosis nigricans, markedly increased BMI and appetite. 9, 10
• McCune‑Albright syndrome: early‑onset GH excess from age 3, café‑au‑lait macules, fibrous dysplasia, and precocious puberty. 9, 10
• Carney complex: characteristic skin pigmentation, cardiac and cutaneous myxomas, and testicular/adrenal disease. 9, 10
• Familial isolated pituitary adenomas (FIPA) with AIP mutations: a positive family history of pituitary adenomas. 9

Diagnostic Algorithm (Key Steps)

• Obtain serial height measurements and review growth charts to define disease onset and trajectory. 9, 10
• Measure age‑, sex‑, and Tanner‑stage‑adjusted serum IGF‑1 as the first‑line screen. 9, 10
• If IGF‑1 is elevated, conduct an OGTT with GH assays, recognizing the ~30 % false‑positive rate in tall youths. 9, 10
• Evaluate prolactin (when available), TSH, and gonadotropins to detect co‑secretion and mass‑effect sequelae. 9, 10
• Perform contrast‑enhanced pituitary MRI after biochemical confirmation of GH excess.
• Carry out comprehensive genetic testing, including targeted panels for X‑LAG, McCune‑Albright, Carney complex, and FIPA. 9
• Obtain a hand radiograph for bone‑age assessment; delayed bone age despite tall stature supports the diagnosis of gigantism. 10

Critical Pitfalls to Avoid

• Do not rely solely on GH‑suppression testing in adolescents, given the ~30 % false‑positive rate in tall children without GH excess. 10
• Do not overlook genetic testing; identifying a mutation in ~50 % of cases guides family screening and counseling. 9
• Do not interpret IGF‑1 in isolation—consider nutritional status, thyroid function, diabetes control, and oral estrogen use. 10
• Ensure serial height measurements and photographic documentation are performed to accurately determine disease onset and progression. 9, 10